| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:40 UTC |
|---|
| HMDB ID | HMDB0014571 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Triprolidine |
|---|
| Description | Triprolidine is only found in individuals that have used or taken this drug. It is the first generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. [PubChem]Triprolidine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. |
|---|
| Structure | CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1 InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+ |
|---|
| Synonyms | | Value | Source |
|---|
| (e)-2-[3-(1-Pyrrolidinyl)-1-p-toluenepropenyl]pyridine | ChEBI | | trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene | ChEBI | | trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene | ChEBI | | trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine | ChEBI | | Tripolidina | ChEBI | | Triprolidinum | ChEBI | | Hydrochloride anhydrous, triprolidine | HMDB | | Triprolidine hydrochloride anhydrous | HMDB | | Hydrochloride, triprolidine | HMDB | | Triprolidine monohydrochloride | HMDB | | Triprolidine monohydrochloride, monohydrate | HMDB | | Triprolidine oxalate, (trans)-isomer | HMDB | | Triprolidine hydrochloride | HMDB | | Triprolidine monohydrochloride, (Z)-isomer | HMDB | | Actidil | HMDB | | Anhydrous, triprolidine hydrochloride | HMDB | | Pro actidil | HMDB | | Triprolidine oxalate | HMDB | | Triprolidine, (Z)-isomer | HMDB | | Wellcome brand OF triprolidine | HMDB |
|
|---|
| Chemical Formula | C19H22N2 |
|---|
| Average Molecular Weight | 278.3914 |
|---|
| Monoisotopic Molecular Weight | 278.178298714 |
|---|
| IUPAC Name | 2-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridine |
|---|
| Traditional Name | triprolidine |
|---|
| CAS Registry Number | 486-12-4 |
|---|
| SMILES | CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1 |
|---|
| InChI Identifier | InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+ |
|---|
| InChI Key | CBEQULMOCCWAQT-WOJGMQOQSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Styrenes |
|---|
| Direct Parent | Styrenes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Styrene
- Toluene
- Pyridine
- N-alkylpyrrolidine
- Pyrrolidine
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Organoheterocyclic compound
- Azacycle
- Hydrocarbon derivative
- Organopnictogen compound
- Amine
- Organic nitrogen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 60 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.054 g/L | Not Available | | LogP | 4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter)). Predicted by Afia on May 17, 2022. | 6.11 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.8684 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.38 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 37.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1516.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 250.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 185.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 179.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 185.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 506.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 470.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 130.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1142.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 354.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1263.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 317.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 301.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 371.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 245.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 16.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Triprolidine EI-B (Non-derivatized) | splash10-0a4i-2690000000-a4b47440bb135b0a9add | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Triprolidine EI-B (Non-derivatized) | splash10-0a4i-2690000000-a4b47440bb135b0a9add | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Triprolidine GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-9550000000-61fa9fbbd86c1d8132d5 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Triprolidine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Triprolidine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 10V, Positive-QTOF | splash10-004i-0090000000-57d0a53f4f4fbf44333e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 20V, Positive-QTOF | splash10-0560-3190000000-e5e446529606f5e3e26c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 40V, Positive-QTOF | splash10-0ae9-9760000000-9bf046a80ce2090309e5 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 10V, Negative-QTOF | splash10-004i-0090000000-f32aa6a085f862b1f8e5 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 20V, Negative-QTOF | splash10-00b9-6190000000-81f7c9adb1e5c8d01951 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 40V, Negative-QTOF | splash10-00di-9010000000-f391092305f35968f4a2 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 10V, Positive-QTOF | splash10-0a6r-0090000000-1bd83ede0cbeecafcb5f | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 20V, Positive-QTOF | splash10-0a4i-0190000000-f7eb5282af1d309096f0 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 40V, Positive-QTOF | splash10-0a5c-5790000000-dd4dd9f6e9e6f3da20c8 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 10V, Negative-QTOF | splash10-004i-0290000000-ba238a298ca7561c0f88 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 20V, Negative-QTOF | splash10-004i-2590000000-f5506cf2d6662537e1c9 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triprolidine 40V, Negative-QTOF | splash10-0a6u-2950000000-7eac67d12b72f0fe7d93 | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44. [PubMed:2568212 ]
- Simons FE: H1-receptor antagonists. Comparative tolerability and safety. Drug Saf. 1994 May;10(5):350-80. [PubMed:7913608 ]
- Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055 ]
- Telekes A, Holland RL, Withington DA, Peck AW: Effects of triprolidine and dipipanone in the cold induced pain test, and the central nervous system of healthy volunteers. Br J Clin Pharmacol. 1987 Jul;24(1):43-50. [PubMed:3620284 ]
|
|---|